473,473 results match your criteria Breast Cancer: Basic and Clinical Research [Journal]


Palbociclib and Fulvestrant in Breast Cancer. Reply.

N Engl J Med 2019 Feb;380(8):797

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1816595DOI Listing
February 2019
1 Read

Palbociclib and Fulvestrant in Breast Cancer.

N Engl J Med 2019 02;380(8):796

Max Institute of Cancer Care, New Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1816595DOI Listing
February 2019

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

N Engl J Med 2019 02;380(8):741-751

From the Massachusetts General Hospital Cancer Center (A.B., S.J.I.) and Dana-Farber Cancer Institute (S.M.T.), Harvard Medical School, Boston; Vanderbilt-Ingram Cancer Center, Nashville (I.A.M., V.G.A.); Weill Cornell Medical College (L.T.V.) and New York-Presbyterian-Columbia University Irving Medical Center (K.K.), New York; University of Colorado Cancer Center, Aurora (J.R.D.); Texas Oncology, Baylor University Medical Center, US Oncology, Dallas (J.O.); Orlando Health University of Florida Health Cancer Center, Orlando (R.L.M., N.C.S.); Yale University School of Medicine, New Haven, CT (A.D.S.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Immunomedics, Morris Plains, NJ (D.M.G., R.I., S.W., R.M.S., W.A.W.); and AIS Consulting, Ann Arbor, MI (A.M.S.).

Background: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. Read More

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814213
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814213DOI Listing
February 2019
2 Reads

Maternal Health Outcomes for Incarcerated Women: A Scoping Review.

J Clin Nurs 2019 Feb 20. Epub 2019 Feb 20.

Dalhousie University's, School of Nursing, Associate Dean Academic, , Dalhousie, University's Faculty of Health; Nurse, IWK Health Centre, Halifax, Nova Scotia.

Aims And Objectives: This scoping review uses intersectional feminism to inform a systematic synthesis of what is known about the maternal health outcomes of incarcerated women.

Background: Despite rising imprisonment of women, there is a lack of research, from a feminist perspective, on perinatal health outcomes among incarcerated women.

Design: Systematic scoping review using the Joanna Briggs Institute scoping review methodology. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jocn.14837
Publisher Site
http://dx.doi.org/10.1111/jocn.14837DOI Listing
February 2019
1 Read

Factors affecting tamoxifen metabolism in breast cancer patients; preliminary results of the French PHACS study (NCT01127295).

Clin Pharmacol Ther 2019 Feb 20. Epub 2019 Feb 20.

Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France.

In addition to the effect of CYP2D6 genetic polymorphisms, the metabolism of tamoxifen may be impacted by other factors with possible consequences on therapeutic outcome (efficacy, toxicity). This analysis focused on the pharmacokinetic-pharmacogenetic evaluation of tamoxifen in 730 adjuvant breast cancer patients included in a prospective multicenter study. Plasma concentrations of tamoxifen and six major metabolites, the genotype for 63 single nucleotide polymorphisms and co-medications were obtained 6 months after treatment initiation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cpt.1404
Publisher Site
http://dx.doi.org/10.1002/cpt.1404DOI Listing
February 2019
1 Read

Density of bone metastatic lesions increases after radiotherapy in patients with breast cancer.

J Radiat Res 2019 Feb 20. Epub 2019 Feb 20.

Department of Radiation Oncology, 307 Hospital of People's Liberation Army, Beijing, China.

The aim of this study was to assess local response to radiotherapy (RT) in a quantitative manner by evaluating the bone density of metastases. Spinal and pelvic bone metastases in 44 patients with breast cancer who were treated between May 2010 and December 2016 were retrospectively assessed. Bone density values of irradiated and unirradiated bone metastases before, 1-3 months after, 4-6 months after, and 7-9 months after RT were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jrr/rry098DOI Listing
February 2019

Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment.

PLoS One 2019 20;14(2):e0212309. Epub 2019 Feb 20.

Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

The Ki-67 labeling index (LI) is an important prognostic factor in breast carcinoma. The Ki-67 LI is traditionally calculated via unaided microscopic estimation; however, inter-observer and intra-observer variability and low reproducibility are problems with this visual assessment (VA) method. For more accurate assessment and better reproducibility with Ki-67 LI, digital image analysis was introduced recently. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212309PLOS
February 2019

Preliminary results of identification and quantification of paclitaxel and its metabolites in human meconium from newborns with gestational chemotherapeutic exposure.

PLoS One 2019 20;14(2):e0211821. Epub 2019 Feb 20.

AJ Drexel Autism Institute, Drexel University, Philadelphia, Pennsylvania, United States of America.

Objective: Cancer diagnosis during pregnancy occurs in 1 out of 1000 pregnancies with common malignancies including breast and hematological cancers. Fetal exposure to currently utilized agents is poorly described. We directly assessed fetal exposure by screening meconium from 23 newborns whose mothers had undergone treatment for cancer during pregnancy. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211821PLOS
February 2019

Development of a human milk concentrate with human milk lyophilizate for feeding very low birth weight preterm infants: A preclinical experimental study.

PLoS One 2019 20;14(2):e0210999. Epub 2019 Feb 20.

Department of Pediatrics, Neonatology, Children´s Hospital, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Breast milk is considered the gold standard nutritional resource for very low birth weight (VLBW) infants in terms of nutrients and protective factors. If mother's milk is not available, the second choice is donated and fortified human milk (HM) from the Human Milk Bank (HMB). This study hypothesized that HM could be lyophilized and used as an additive to increase the levels of macronutrients and micronutrients available to VLBW infants. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210999PLOS
February 2019

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.

J Clin Oncol 2019 Feb 20:JCO1800028. Epub 2019 Feb 20.

1 West German Study Group, Mönchengladbach, Germany.

Purpose: The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC).

Patients And Methods: Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00028DOI Listing
February 2019

Green Breast Milk Following Ingestion of Blue-Green Algae: A Case Report.

Breastfeed Med 2019 Feb 20. Epub 2019 Feb 20.

1 Department of Neonatology, The Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Breast milk is an excellent nutritional source for newborns, and a change in its color can be alarming to both mother and physician, and may prevent breastfeeding. Different colors of breast milk have been reported such as blood-stained, blue, and bluish-green. We present the first case of green breast milk caused by maternal ingestion of blue-green algae pills immediately before and after delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/bfm.2018.0184DOI Listing
February 2019

Lymphedema after Breast Cancer Treatment.

Authors:
Ayad Jindeel

N Engl J Med 2019 Feb 14;380(7):694. Epub 2019 Feb 14.

View Article

Download full-text PDF

Source
February 2019

Association between hereditary predisposition to common cancers and congenital multimalformations.

Congenit Anom (Kyoto) 2019 Feb 20. Epub 2019 Feb 20.

Centre Jean Perrin (Comprehensive Cancer Center), Clermont-Ferrand, France.

Introduction: in a previous article we reported that mutations favoring cancer at adulthood seemed to improve fertility and limit miscarriages. Because spontaneous abortion may result from anomalies in embryo, we questioned if an increased frequency of congenital malformation could be evidenced among cancer prone families.

Methods: oncogenetics database (≈193,000 members) of the comprehensive cancer center Jean Perrin was crossed with regional registry of congenital malformations (≈10,000). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cga.12329DOI Listing
February 2019

The Effectiveness and Safety of Utilizing Mobile Phone-Based Programs for Rehabilitation After Lumbar Spinal Surgery: Multicenter, Prospective Randomized Controlled Trial.

JMIR Mhealth Uhealth 2019 Feb 20;7(2):e10201. Epub 2019 Feb 20.

Department of Orthopedics, 8th Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, China.

Background: Rehabilitation is crucial for postoperative patients with low back pain (LBP). However, the implementation of traditional clinic-based programs is limited in developing countries, such as China, because of the maldistribution of medical resources. Mobile phone-based programs may be a potential substitute for those who have no access to traditional rehabilitation. Read More

View Article

Download full-text PDF

Source
http://mhealth.jmir.org/2019/2/e10201/
Publisher Site
http://dx.doi.org/10.2196/10201DOI Listing
February 2019
1 Read

Circular RNA expression in exosomes derived from breast cancer cells and patients.

Epigenomics 2019 Feb 20. Epub 2019 Feb 20.

Center of Clinical Laboratory Science, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, PR China.

Aim: We aimed to explore the roles of circular RNAs (circRNAs) in breast cancer (BCa).

Materials & Methods: RNA was extracted from exosomes and BCa cells and analyzed using the RNA sequencing technique or microarray.

Results: Compared with controls, 1147 and 1195 circRNAs were dysregulated in exosomes from metastatic and localized BCa patients, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi-2018-0111DOI Listing
February 2019

Comparing provider and patient views of issues for low resourced breast cancer patients.

Psychooncology 2019 Feb 20. Epub 2019 Feb 20.

University of Washington.

Objective: The purpose of this study was to compare provider and patient views from the same clinical settings on issues raised by low socioeconomic status (SES) breast cancer survivors.

Methods: We conducted qualitative interviews among two groups: low SES breast cancer survivors (n=37) and medical personnel (ie, physicians, nurses, navigators; n=8) that interact and serve with these patients from two geographically distinct low resourced clinical settings. These semi-structured qualitative interviews used grounded theory to identify several potential themes, such as finances, resources, and medical care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.5035DOI Listing
February 2019

Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.

Cancer Treat Res Commun 2019 Feb 6;19:100121. Epub 2019 Feb 6.

West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, United States.

Purpose: This retrospective study of community oncology patients with breast cancer gene (BRCA)-mutated metastatic breast cancer (MBC) examined treatment outcomes and health resource utilization (HRU) and costs for a sample of patients with human epidermal growth factor receptor 2 (HER2)-negative disease who were either hormone receptor positive (HR+) or triple negative breast cancer (TNBC).

Methods: Evidence from the Vector Oncology Data Warehouse, a repository of electronic medical records/billing data and provider notes, was analyzed. Treatment outcomes were progression-free survival (PFS) and overall survival (OS) from start of first-line therapy in the metastatic setting. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942183013
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2019.100121DOI Listing
February 2019
6 Reads

Is human papillomavirus associated with breast cancer or papilloma presenting with pathologic nipple discharge?

Cancer Treat Res Commun 2019 Feb 6;19:100122. Epub 2019 Feb 6.

Breast Surgery, Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, New York, NY, USA.

Purpose: There are little data on the presence or interaction of human papillomavirus (HPV) in intraductal papilloma or Breast cancer (BC) presenting with pathologic nipple discharge (PND). The study aimed to determine whether the HPV-genotypes are identifiable in papilloma or carcinoma of the breast by real-time PCR with broad-spectrum genotyping.

Methods: Formalin-fixed-paraffin-blocks obtained from the patients who were suffering from PND and underwent ductoscopic papilloma extraction (n = 27) or segmental/total mastectomy for cancer diagnosis (n = 18). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100122DOI Listing
February 2019

Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015.

Breast 2019 Feb 11;44:153-159. Epub 2019 Feb 11.

ANU Medical School, Australian National University, Barry Drive, Acton, ACT 0200, Australia; Health Analytics Research Centre, ACT Health, GPO Box 825, ACT 2601, Australia.

Background: Evidence suggests recent improvements in outcome in early breast cancer (EBC).

Aim: To analyse recurrence in women with EBC from our region from 1997 to 2015.

Methods: We analysed recurrence in 3,765 women with EBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.004DOI Listing
February 2019

Novel 2,4-disubstituted quinazolines as cytotoxic agents and JAK2 inhibitors: Synthesis, in vitro evaluation and molecular dynamics studies.

Comput Biol Chem 2019 Jan 21;79:110-118. Epub 2019 Jan 21.

Centre for Molecular Cancer Research (CMCR), Vishnu Institute of Pharmaceutical and Educational Research, Narsapur, India. Electronic address:

Recent studies reported the involvement of JAK2/STAT3 pathway in various solid tumours including breast, ovarian, prostate and lung cancers. Clinical literature also reported the lowered burden in breast and ovarian cancers by targeting JAK2 pathway. In this study, a series of novel 2,4-disubstituted quinazolines (2a-2 j and 3a-3 j) were synthesized and were evaluated for their cytotoxicity against human breast cancer (MDA-MB-231) and ovarian cancer (SK-O-V3) cell lines using MTT assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiolchem.2019.01.008DOI Listing
January 2019

Network-pharmacology-based identification of caveolin-1 as a key target of Oldenlandia diffusa to suppress breast cancer metastasis.

Biomed Pharmacother 2019 Feb 20;112:108607. Epub 2019 Feb 20.

Integrative Research Laboratory of Breast Cancer, Discipline of Integrated Chinese and Western Medicine, the Research Center of Integrative Medicine, School of Basic Medical Sciences & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China; Post-doctoral Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. Electronic address:

Background: Breast cancer remains the most common female malignancy and metastasis is the leading cause of death in breast cancer patients. Oldenlandia diffusa has been empirically and extensively used as an adjuvant therapy for metastatic breast cancer patients in Traditional Chinese Medicine (TCM) with proven efficacy. However, its anti-metastasis mechanism has been poorly revealed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.108607DOI Listing
February 2019

Synthesis, in vitro and in vivo biological evaluation of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones as new potent anticancer agents.

Eur J Med Chem 2019 Jan 26;166:514-530. Epub 2019 Jan 26.

Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia, Università di Padova, 35128, Padova, Italy. Electronic address:

A small library of 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones has been synthesized and screened according to protocols available at the National Cancer Institute (NCI). Some derivatives were potent antiproliferative agents, showing GI values in the nanomolar range. Remarkably, when most active compounds against leukemia cells were tested in human peripheral blood lymphocytes from healthy donors, were 100-200 times less cytotoxic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2019.01.049DOI Listing
January 2019
3.447 Impact Factor

Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.

Eur J Med Chem 2019 Feb 12;167:485-498. Epub 2019 Feb 12.

State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, PR China. Electronic address:

A series of novel B and C-rings truncated deguelin derivatives have been designed and synthesized in the present study as heat shock protein 90 (Hsp90) inhibitors. The synthesized compounds exhibited micromolar antiproliferative potency toward a panel of human cancer cell lines. Their structure-activity relationships (SARs) were investigated in a systematic manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2019.02.014DOI Listing
February 2019

Negotiating jurisdictional boundaries in response to new genetic possibilities in breast cancer care: The creation of an 'oncogenetic taskscape'.

Soc Sci Med 2019 Feb 13;225:26-33. Epub 2019 Feb 13.

Ethox Centre and Wellcome Centre for Ethics and Humanities, Nuffield Department of Population Health, Big Data Institute University of Oxford, UK.

Changes in the nature and structure of healthcare pathways have implications for healthcare professionals' jurisdictional boundaries. The introduction of treatment focused BRCA1 and 2 genetic testing (TFGT) for newly diagnosed patients with breast cancer offers a contemporary example of pathway change brought about by technological advancements in gene testing and clinical evidence, and reflects the cultural shift towards genomics. Forming part of an ethnographically informed study of patient and practitioner experiences of TFGT at a UK teaching hospital, this paper focuses on the impact of a proposal to pilot a mainstreamed TFGT pathway on healthcare professionals' negotiations of professional jurisdiction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.socscimed.2019.02.020DOI Listing
February 2019

Effect of thermal manipulation during embryogenesis on the promoter methylation and expression of myogenesis-related genes in duck skeletal muscle.

J Therm Biol 2019 Feb 26;80:75-81. Epub 2018 Dec 26.

Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, PR China. Electronic address:

Avian embryos are an ideal system to investigate the effect of incubation temperature on embryonic development, but the characteristics and mechanisms of temperature effects on poultry embryonic myogenesis are unclear. In this study, we investigated the effect of increasing the incubation temperature by 1 °C on the expression of nine myogenesis-related genes in ducks and then explored the correlation between the alteration of promoter methylation and the expression of two of the nine genes under thermal manipulation (TM). The qRT-PCR results showed that TM during embryonic days (ED) 1-10 promoted (P < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtherbio.2018.12.023DOI Listing
February 2019

High expression of carbonic anhydrase 12 (CA12) is associated with good prognosis in breast cancer.

Neoplasma 2019 Feb 20. Epub 2019 Feb 20.

The purpose of this research was to explore whether the expression of carbonic anhydrase 12 (CA12) and the prognosis had a significant relationship in breast cancer patients. A total of 262 breast cancer specimens and 75 normal breast tissue specimens were recruited in this study. The expression of CA12 was detected by immunohistochemistry (IHC), and its correlation with the clinicopathological characteristics of breast cancer patients and their prognosis were further analyzed through standard statistical algorithms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2018_180819N624DOI Listing
February 2019

Ambra1 inhibits paclitaxel-induced apoptosis in breast cancer cells by modulating the Bim/mitochondrial pathway.

Neoplasma 2019 Feb 20. Epub 2019 Feb 20.

Cancer cells often evade apoptosis induced by anti-cancer drugs, which reduces the efficacy of the drugs. Autophagy/Beclin 1 regulator 1 (Ambra1) is a crucial proautophagic protein. It also plays an important role in the execution of apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2018_180710N467DOI Listing
February 2019

Bioactivity-Guided Isolation of Totarane-Derived Diterpenes from Podocarpus neriifolius and Structure Revision of 3-Deoxy-2α-hydroxynagilactone E.

Nat Prod Bioprospect 2019 Feb 19. Epub 2019 Feb 19.

Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, College of Pharmacy, Columbus, OH, USA.

Bioactivity-guided phytochemical investigation of Podocarpus neriifolius D. Don. (Podocarpaceae) has led to the isolation of one new (2) and three known (1, 3, and 4) B-type podolactones, along with three totarane-type diterpenes (5-7). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13659-019-0198-xDOI Listing
February 2019

Amyloid tumor of the breast.

Surg Case Rep 2019 Feb 19;5(1):31. Epub 2019 Feb 19.

Department of Breast Oncology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

Background: Amyloid tumor of the breast is a rare disease, which was first reported in 1973. To date, only six cases have been reported in Japan.

Case Presentation: A 45-year-old woman who had a medical history of Sjogren's syndrome presented with a lump of 3 cm in diameter on the outer side of the right breast. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0591-zDOI Listing
February 2019

Rural-urban differences in health behaviors and outcomes among older, overweight, long-term cancer survivors in the RENEW randomized control trial.

Cancer Causes Control 2019 Feb 19. Epub 2019 Feb 19.

Department of Nutrition Sciences, UAB, Birmingham, AL, USA.

Purpose: Rural cancer survivors (RCS) have poorer health outcomes and face multiple challenges-older age, and limited transportation, education, income, and healthcare access. Yet, RCS are understudied. The Reach-out to ENhancE Wellness(RENEW) trial, a home-based, diet and exercise intervention among 641 breast, prostate, and colorectal cancer survivors addressed many of these challenges. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-019-01141-xDOI Listing
February 2019

ASO Author Reflections: Breast Center Accreditation and Performance: Impact on Patient Care?

Ann Surg Oncol 2019 Feb 19. Epub 2019 Feb 19.

The Data Working Group, National Accreditation Program for Breast Centers, American College of Surgeons, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07246-6DOI Listing
February 2019

Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.

Ann Surg Oncol 2019 Feb 19. Epub 2019 Feb 19.

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Malignant/borderline phyllodes tumors (PTs) are rare, and little is known about their long-term prognosis. This study sought to evaluate recurrence rates and identify factors associated with local and distant failure.

Methods: From 1957 to 2017, we identified 124 patients with 125 PTs (86 malignant and 39 borderline). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07210-4DOI Listing
February 2019

ASO Author Reflections: Role of Genomic Assay to Predict Neoadjuvant Chemotherapy Response in Breast Cancer.

Ann Surg Oncol 2019 Feb 19. Epub 2019 Feb 19.

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07244-8DOI Listing
February 2019

The impact of EndoPredict on decision making with increasing oncological work experience: can overtreatment be avoided?

Arch Gynecol Obstet 2019 Feb 19. Epub 2019 Feb 19.

Breast Cancer Center, Municipal Hospital Holweide, Cologne, Germany.

Background: Estimating distant recurrence risk in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer is still challenging. EndoPredict is a gene expression-based test predicting the likelihood of recurrent disease. We analyzed the difference in oncological decision making with and without the knowledge of gene expression tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05097-wDOI Listing
February 2019

Trauma on a Recently Augmented Breast as a Trigger for Mondor's Disease.

Aesthetic Plast Surg 2019 Feb 19. Epub 2019 Feb 19.

Adella Aesthetic, 15G, Tintyava Str., 1172, Sofia, Bulgaria.

Mondor's disease is the eponym used to describe a self-limited phlebitis or thrombophlebitis of the superficial veins localized mainly on the thoracoabdominal area of the human body. Its clinical manifestation includes painful superficial cords causing skin retraction. This medical condition could be idiopathic, iatrogenic or a manifestation of underlying pathology such as breast cancer and seems to be more common than has been previously thought. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00266-019-01331-7DOI Listing
February 2019

Patient-Reported Outcome Measures for Breast Implant Surgery: A Pilot Study.

Aesthet Surg J 2019 Feb 3. Epub 2019 Feb 3.

Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Background: The Breast-Q Implant Surveillance (BREAST-Q IS) is a patient-reported outcome measure (PROM) asking five questions on satisfaction (shape, feel, and rippling) and symptoms (pain and tightness) derived from the BREAST-Q.

Objectives: We aimed to pilot BREAST-Q IS on patients within the Australian Breast Device Registry (ABDR), an opt-out clinical quality device registry, and explored Short Message Service (SMS) for follow up.

Methods: Patients with a breast device surgery in the previous 10-15 months, age ≥18, with a mobile phone number, were invited to complete the 5-question PROM via SMS initially, followed by three phone call attempts if no response, an email, and then a letter by post as a final engagement strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjz023DOI Listing
February 2019

Formation of precisely composed cancer cell clusters using a cell assembly generator (CAGE) for studying paracrine signaling at single-cell resolution.

Lab Chip 2019 Feb 20. Epub 2019 Feb 20.

Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.

The function and behaviour of any given cell in a healthy tissue, or in a tumor, is affected by interactions with its neighboring cells. It is therefore important to create methods that allow for reconstruction of tissue niches in vitro for studies of cell-cell signaling and associated cell behaviour. To this end we created the cell assembly generator (CAGE), a microfluidic device which enables the organization of different cell types into precise cell clusters in a flow chamber compatible with high-resolution microscopy. Read More

View Article

Download full-text PDF

Source
http://xlink.rsc.org/?DOI=C8LC01153B
Publisher Site
http://dx.doi.org/10.1039/c8lc01153bDOI Listing
February 2019
1 Read

Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers.

Oncotarget 2019 Jan 25;10(8):916. Epub 2019 Jan 25.

Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

[This corrects the article DOI: 10.18632/oncotarget.6006. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368237PMC
January 2019

Pregnancies in young women with diagnosis and treatment of HER2-positive breast cancer.

Oncotarget 2019 Jan 25;10(8):803-804. Epub 2019 Jan 25.

Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26611DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368228PMC
January 2019

HOXA1 upregulation is associated with poor prognosis and tumor progression in breast cancer.

Exp Ther Med 2019 Mar 28;17(3):1896-1902. Epub 2018 Dec 28.

Department of Breast Surgery, Dalian Central Hospital Affiliated to Dalian Medical University, Dalian, Liaoning 116033, P.R. China.

Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer-associated mortality among females worldwide. As a member of the homeobox (HOX) gene family, HOXA1 is involved in tumor progression and prognosis in several types of human cancer. However, the clinical significance and biological functions of HOXA1 in BC remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364196PMC

Analysis of the causes of false negative and false positive results of preoperative axillary ultrasound in patients with early breast cancer - a single-centre study.

Contemp Oncol (Pozn) 2018 31;22(4):247-251. Epub 2018 Dec 31.

Chair and Department of Surgical Oncology, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

Introduction: Properly planned and performed diagnostic tests allow the optimal treatment option to be chosen for the patient. They also allow qualification for the correct surgical procedure.

Aim Of The Study: In this study we evaluated the clinical value of preoperative ultrasound scan (USS) testing performed during primary disease staging in patients with early breast cancer qualified to sentinel lymph node biopsy (SLNB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/wo.2018.82644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377422PMC
December 2018

Evaluation of distant sequelae of breast cancer treatment among patients after breast-conserving surgery depending on the type of intervention in the axillary fossa.

Contemp Oncol (Pozn) 2018 31;22(4):240-246. Epub 2018 Dec 31.

Department of Rehabilitation, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

Aim Of The Study: The goal of this work was to assess upper-limb sequelae among patients undergoing breast-conserving therapy (BCT) for breast cancer 5-6 years after the surgical procedure.

Material And Methods: A controlled clinical study was conducted on 128 patients who had undergone surgery 5-6 years prior. BCT + ALND (axillary lymph node dissection) was performed in 58 patients and 69 underwent BCT + SLND (sentinel lymph node dissection). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/wo.2018.82643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377421PMC
December 2018

Analysis of Treg cell population in patients with breast cancer with respect to progesterone receptor status.

Contemp Oncol (Pozn) 2018 31;22(4):236-239. Epub 2018 Dec 31.

Department of Oncology, Radiotherapy, and Gynecologic Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

Breast cancer is the most frequently diagnosed type of cancer in women worldwide. Both the development and progression of breast cancer are related to tumour evasion of the immune system through a process called cancer immune-editing, in which regulatory lymphocytes play an important role. The infiltration of Treg cells in patients with breast cancer has been proposed as an independent unfavourable prognostic factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/wo.2018.80038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377420PMC
December 2018

The repair using a fibular graft of cervical vertebral collapse due to renal cell carcinoma: Late results with a case report.

J Craniovertebr Junction Spine 2018 Oct-Dec;9(4):267-270

Department of Pathology, Research and Training Hospital, Recep Tayyip Erdogan University, Rize, Turkey.

The most common cause of spinal tumors is metastases, but the cervical vertebra is the least common region of spinal metastasis, and relatively, little is published about surgery in metastasis to the cervical vertebra. While spinal metastasis is most often caused by neoplasms originating from the lung, breast, and prostate, renal cell carcinoma (RCC) metastasis is very rare. A 47-year-old patient introduced here presented with severe pain spontaneously on his neck and in his arm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcvjs.JCVJS_32_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364372PMC
February 2019

A case of capecitabine-induced dermatomyositis.

Indian J Pharmacol 2018 Nov-Dec;50(6):350-353

Department of Dermatology, MLN Medical College, Allahabad, Uttar Pradesh, India.

Dermatomyositis (DM) is an idiopathic, inflammatory connective tissue disorder characterized by symmetrical proximal myopathy and characteristic skin involvement. The pathogenesis of DM is widely debated; however, it is postulated to be an end result of immune-mediated cascade, triggered by multiple environmental factors in a genetically predisposed individual. In addition to underlying malignancies, many drugs have been reported to be associated with DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijp.IJP_356_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364339PMC
February 2019

Baby's mouth might hold sway over breast-milk microbiome.

Authors:

Nature 2019 Feb;566(7744):299

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41586-019-00568-1DOI Listing
February 2019

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.

Br J Cancer 2019 Feb 20. Epub 2019 Feb 20.

Clinical Research Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK.

Background: Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.

Methods: In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tumours received eribulin mesilate intravenously in 21-day cycles according to schedule 1 (day 1) or schedule 2 (days 1, 8) with twice-daily oral capecitabine (1000 mg/m days 1-14). In phase 2 (dose confirmation), women with advanced/MBC and ≤3 prior chemotherapies received eribulin mesilate at the maximum tolerated dose (MTD) per the preferred schedule plus capecitabine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0366-5DOI Listing
February 2019

MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer.

Br J Cancer 2019 Feb 20. Epub 2019 Feb 20.

School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD, Australia.

Background: MicroRNAs are potent post-transcriptional regulators involved in all hallmarks of cancer. Mir-196a is transcribed from two loci and has been implicated in a wide range of developmental and pathogenic processes, with targets including Hox, Fox, Cdk inhibitors and annexins. Genetic variants and altered expression of MIR196A are associated with risk and progression of multiple cancers including breast cancer, however little is known about the regulation of the genes encoding this miRNA, nor the impact of variants therein. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0395-8
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0395-8DOI Listing
February 2019
1 Read